About us

Drug design, not discovery.

AI that transforms imagination into breakthrough medicines.

Misson & Vision

We aim to redefine how therapeutics are developed: shifting from traditional, screening-based discovery to rational design powered by AI.
We envision an ideal platform that enables the zero-shot design of optimal molecules, without relying on trial-and-error or pre-existing templates.
We believe that an accurate drug design platform will streamline therapeutic development and deliver safer, more effective medicines to patients.

Our story

Built on science, driven by purpose

Our journey began with a deep passion to understand biology at the molecular level.

For more than 20 years, our team at Seoul National University has pioneered protein structure prediction and design technologies, earning global recognition for scientific excellence.


Where expertise sparks innovation

Driven by deep domain expertise, Galux was founded in 2020 with a passion to streamline drug development and address the limitations of conventional discovery through AI.


Technological excellence sets us apart

We are at the forefront of AI-driven protein design as one of the few groups to have successfully demonstrated de novo antibody design. Our platform's unprecedented accuracy and generalizability have been validated through the de novo design of antibodies, one of the most challenging protein classes, across multiple therapeutic targets.


Shaping the future of AI drug discovery and development

This is just the beginning. We move fast to accelerate the arrival of the next generation of medicine,
so that more people living today can benefit.

Latest news

Galux and HanAll Biopharma Initiate Strategic Collaboration to Develop AI-Designed Antibody Therapeutics for Cancer
Read More
Pioneering Precision: How South Korea's Galux is Redefining Antibody Discovery with AI
Read More
Korean AI firm Galux develops six novel therapeutic antibodies using innovative design methods
Read More